ORGO gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 525 industry peers in the Biotechnology industry. Both the profitability and the financial health of ORGO get a neutral evaluation. Nothing too spectacular is happening here. ORGO has a decent growth rate and is not valued too expensively.

Quickly go to:

1. Profitability

2. Health

3. Growth

4. Valuation

5. Dividend

1. Profitability

1.1 Basic Checks

ORGO had positive earnings in the past year.
In the past year ORGO has reported a negative cash flow from operations.
ORGO had positive earnings in 4 of the past 5 years.
In the past 5 years ORGO always reported a positive cash flow from operatings.

1.2 Ratios

ORGO has a better Return On Assets (-2.63%) than 87.43% of its industry peers.
The Return On Equity of ORGO (-3.47%) is better than 89.14% of its industry peers.
ORGO has a Return On Invested Capital of 0.16%. This is amongst the best in the industry. ORGO outperforms 88.76% of its industry peers.
The Average Return On Invested Capital over the past 3 years for ORGO is significantly below the industry average of 18.07%.

		Industry Rank	Sector Rank
ROA	-2.63%
ROE	-3.47%
ROIC	0.16%

ROA(3y)1.45%

ROA(5y)6.32%

ROE(3y)2.46%

ROE(5y)11.67%

ROIC(3y)3.79%

ROIC(5y)7.32%

1.3 Margins

ORGO's Operating Margin of 0.18% is amongst the best of the industry. ORGO outperforms 88.76% of its industry peers.
ORGO's Operating Margin has declined in the last couple of years.
The Gross Margin of ORGO (74.49%) is better than 83.43% of its industry peers.
In the last couple of years the Gross Margin of ORGO has remained more or less at the same level.

		Industry Rank	Sector Rank
OM	0.18%
PM (TTM)	N/A
GM	74.49%

OM growth 3Y-34.07%

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y0.17%

GM growth 5Y1.4%

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

ORGO has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
Compared to 1 year ago, ORGO has less shares outstanding
ORGO has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, ORGO has an improved debt to assets ratio.

2.2 Solvency

ORGO has an Altman-Z score of 3.74. This indicates that ORGO is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of ORGO (3.74) is better than 70.48% of its industry peers.
A Debt/Equity ratio of 0.01 indicates that ORGO is not too dependend on debt financing.
ORGO has a Debt to Equity ratio (0.01) which is comparable to the rest of the industry.

		Industry Rank	Sector Rank
Debt/Equity	0.01
Debt/FCF	N/A
Altman-Z	3.74

ROIC/WACC0.02

WACC9.11%

2.3 Liquidity

ORGO has a Current Ratio of 3.32. This indicates that ORGO is financially healthy and has no problem in meeting its short term obligations.
With a Current ratio value of 3.32, ORGO is not doing good in the industry: 60.19% of the companies in the same industry are doing better.
A Quick Ratio of 2.88 indicates that ORGO has no problem at all paying its short term obligations.
The Quick ratio of ORGO (2.88) is worse than 63.62% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	3.32
Quick Ratio	2.88

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

ORGO shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -90.91%.
Measured over the past years, ORGO shows a very negative growth in Earnings Per Share. The EPS has been decreasing by -37.90% on average per year.
ORGO shows a small growth in Revenue. In the last year, the Revenue has grown by 2.24%.
ORGO shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 13.05% yearly.

EPS 1Y (TTM)-90.91%

EPS 3Y-37.9%

EPS 5YN/A

EPS Q2Q%66.67%

Revenue 1Y (TTM)2.24%

Revenue growth 3Y0.98%

Revenue growth 5Y13.05%

Sales Q2Q%30.98%

3.2 Future

The Earnings Per Share is expected to grow by 29.27% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 8.70% on average over the next years. This is quite good.

EPS Next Y-58%

EPS Next 2Y-6.73%

EPS Next 3Y29.27%

EPS Next 5YN/A

Revenue Next Year9.76%

Revenue Next 2Y8.03%

Revenue Next 3Y8.7%

Revenue Next 5YN/A

3.3 Evolution

When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

Based on the Price/Earnings ratio of 400.00, the valuation of ORGO can be described as expensive.
88.95% of the companies in the same industry are more expensive than ORGO, based on the Price/Earnings ratio.
ORGO is valuated expensively when we compare the Price/Earnings ratio to 28.30, which is the current average of the S&P500 Index.
Based on the Price/Forward Earnings ratio of 27.05, the valuation of ORGO can be described as expensive.
ORGO's Price/Forward Earnings ratio is rather cheap when compared to the industry. ORGO is cheaper than 92.19% of the companies in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 25.57, ORGO is valued at the same level.

		Industry Rank	Sector Rank
PE	400
Fwd PE	27.05

4.2 Price Multiples

ORGO's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. ORGO is cheaper than 93.71% of the companies in the same industry.

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	23.49

4.3 Compensation for Growth

The decent profitability rating of ORGO may justify a higher PE ratio.
A more expensive valuation may be justified as ORGO's earnings are expected to grow with 29.27% in the coming years.